{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:45:10Z","timestamp":1790790310262,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T00:00:00Z","timestamp":1728518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T00:00:00Z","timestamp":1728518400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005765","name":"Universidade de Lisboa","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005765","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Hereditary transthyretin-mediated amyloidosis (ATTRv amyloidosis) is a rare progressively incapacitating condition with a wide range of genotype\/phenotype presentations. It is frequently diagnosed late in its course, particularly in sporadic cases.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Objectives<\/jats:title>\n            <jats:p>Analysing predictors of diagnostic delay in this subpopulation should be, therefore, a priority.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>109 apparently sporadic ATTRv amyloidosis patients followed in a reference centre in Hospital de Santa Maria (ULS Santa Maria-CAML), in Lisbon, were studied. Time from symptom onset to diagnosis, age, sex, municipality of origin and initial symptoms were obtained. Diagnostic delay was compared between different decades with a Kruskal\u2013Wallis test, and its predictors were evaluated in a univariate model followed by a binary logistic regression analysis to calculate the adjusted odds ratio.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The median diagnostic delay was 1262\u00a0days. There was a non-significant difference in diagnostic delay between the 80\u00a0s, 90\u00a0s, 2000s and 2010s decades. There was a non-significant trend for a longer diagnostic delay in woman and in patients having no neurologic symptoms at onset.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>There is an important diagnostic delay in sporadic cases of ATTRv amyloidosis. Awareness should be spread among clinicians regarding the various manifestations of this disease, stressing the importance of family history and epidemiological data.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s10072-024-07793-1","type":"journal-article","created":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T13:01:54Z","timestamp":1728565314000},"page":"929-934","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Diagnostic delay in patients with sporadic hereditary transthyretin-mediated amyloidosis"],"prefix":"10.1007","volume":"46","author":[{"given":"Bernardo","family":"Antunes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0934-9631","authenticated-orcid":false,"given":"Isabel","family":"Concei\u00e7\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6194-9787","authenticated-orcid":false,"given":"Catarina","family":"Falc\u00e3o de Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7556-0158","authenticated-orcid":false,"given":"Mamede","family":"de Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,10]]},"reference":[{"issue":"7","key":"7793_CR1","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41582-019-0210-4","volume":"15","author":"D Adams","year":"2019","unstructured":"Adams D, Koike H, Slama M, Coelho T (2019) Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease-. Nat Rev Neurol 15(7):387\u2013404. https:\/\/doi.org\/10.1038\/s41582-019-0210-4","journal-title":"Nat Rev Neurol"},{"issue":"1\u20132","key":"7793_CR2","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.jns.2009.05.001","volume":"284","author":"G Said","year":"2009","unstructured":"Said G, Plant\u00e9-Bordeneuve V (2009) Familial amyloid polyneuropathy: a clinico-pathologic study. J Neurol Sci 284(1\u20132):149\u2013154. https:\/\/doi.org\/10.1016\/j.jns.2009.05.001","journal-title":"J Neurol Sci"},{"issue":"3\u20134","key":"7793_CR3","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1159\/000490553","volume":"51","author":"M In\u00eas","year":"2018","unstructured":"In\u00eas M, Coelho T, Concei\u00e7\u00e3o I, Duarte-Ramos F, de Carvalho M, Costa J (2018) Epidemiology of transthyretin familial amyloid polyneuropathy in Portugal: a nationwide study. Neuroepidemiology 51(3\u20134):177\u2013182. https:\/\/doi.org\/10.1159\/000490553","journal-title":"Neuroepidemiology"},{"issue":"6","key":"7793_CR4","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1007\/s00415-019-09688-0","volume":"268","author":"D Adams","year":"2021","unstructured":"Adams D, Ando Y, Beir\u00e3o JM, Coelho T, Gertz MA, Gillmore JD, Hawkins PN, Lousada I, Suhr OB, Merlini G (2021) Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy. J Neurol 268(6):2109\u20132122. https:\/\/doi.org\/10.1007\/s00415-019-09688-0","journal-title":"J Neurol"},{"issue":"30","key":"7793_CR5","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","volume":"39","author":"JD Gillmore","year":"2018","unstructured":"Gillmore JD, Damy T, Fontana M, Hutchinson M, Lachmann HJ, Martinez-Naharro A, Quarta CC, Rezk T, Whelan CJ, Gonzalez-Lopez E, Lane T (2018) A new staging system for cardiac transthyretin amyloidosis. Eur Heart J 39(30):2799\u20132806. https:\/\/doi.org\/10.1093\/eurheartj\/ehx589","journal-title":"Eur Heart J"},{"issue":"2","key":"7793_CR6","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1136\/jnnp-2011-301299","volume":"83","author":"H Koike","year":"2012","unstructured":"Koike H, Tanaka F, Hashimoto R, Tomita M, Kawagashira Y, Iijima M, Fujitake J, Kawanami T, Kato T (2012) Natural history of transthyretin Val30Met familial amyloid polyneuropathy:analysis of late-onset cases from non-endemic areas. J Neurol Neurosurg Psychiatry 83(2):152\u2013158. https:\/\/doi.org\/10.1136\/jnnp-2011-301299","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"7793_CR7","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.ahj.2012.04.015","volume":"164","author":"FL Ruberg","year":"2012","unstructured":"Ruberg FL, Maurer MS, Judge DP, Zeldenrust S, Skinner M, Kim AY, Falk RH, Cheung KN, Patel AR, Pano A, Packman J (2012) Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS). Am Heart J 164(2):222-228.e1. https:\/\/doi.org\/10.1016\/j.ahj.2012.04.015","journal-title":"Am Heart J"},{"issue":"11","key":"7793_CR8","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/S1474-4422(23)00334-4","volume":"22","author":"D Adams","year":"2023","unstructured":"Adams D, Sekijima Y, Concei\u00e7\u00e3o I, Waddington-Cruz M, Polydefkis M, Echaniz-Laguna A, Reilly MM (2023) Hereditary transthyretin amyloid neuropathies: advances in pathophysiology, biomarkers, and treatment. Lancet Neurol 22(11):1061\u20131074. https:\/\/doi.org\/10.1016\/S1474-4422(23)00334-4","journal-title":"Lancet Neurol"},{"issue":"3","key":"7793_CR9","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1080\/13506129.2022.2052838","volume":"29","author":"Y Ando","year":"2022","unstructured":"Ando Y, Adams D, Benson MD, Berk JL, Plant\u00e9-Bordeneuve V, Coelho T, Concei\u00e7\u00e3o I, Ericzon BG, Obici L, Rapezzi C, Sekijima Y (2022) Guidelines and new directions in the therapy and monitoring of ATTRv amyloidosis. Amyloid 29(3):143\u2013155. https:\/\/doi.org\/10.1080\/13506129.2022.2052838","journal-title":"Amyloid"},{"issue":"12","key":"7793_CR10","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1007\/s00415-013-7124-7","volume":"260","author":"MF Dohrn","year":"2013","unstructured":"Dohrn MF, R\u00f6cken C, De Bleecker JL, Martin JJ, Vorgerd M, Van den Bergh PY, Ferbert A, Hinderhofer K, Schr\u00f6der JM, Weis J, Schulz JB (2013) Diagnostic hallmarks and pitfalls in late-onset progressive transthyretin-related amyloid-neuropathy. J Neurol 260(12):3093\u20133108. https:\/\/doi.org\/10.1007\/s00415-013-7124-7","journal-title":"J Neurol"},{"issue":"Suppl 2","key":"7793_CR11","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s10072-020-04889-2","volume":"43","author":"F Manganelli","year":"2022","unstructured":"Manganelli F, Fabrizi GM, Luigetti M, Mandich P, Mazzeo A, Pareyson D (2022) Hereditary transthyretin amyloidosis overview. Neurol Sci 43(Suppl 2):595\u2013604. https:\/\/doi.org\/10.1007\/s10072-020-04889-2","journal-title":"Neurol Sci"},{"issue":"Suppl. 1","key":"7793_CR12","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1097\/WCO.0000000000000290","volume":"29","author":"L Obici","year":"2016","unstructured":"Obici L, Kuks JB, Buades J, Adams D, Suhr OB, Coelho T, Kyriakides T (2016) Recommendations for presymptomatic genetic testing and management of individuals at risk for hereditary transthyretin amyloidosis. Curr Opin Neurol 29(Suppl. 1):S27-35. https:\/\/doi.org\/10.1097\/WCO.0000000000000290","journal-title":"Curr Opin Neurol"},{"issue":"1","key":"7793_CR13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1080\/13506129.2018.1556156","volume":"26","author":"I Concei\u00e7\u00e3o","year":"2019","unstructured":"Concei\u00e7\u00e3o I, Damy T, Romero M, Gal\u00e1n L, Attarian S, Luigetti M, Sadeh M, Sarafov S, Tournev I, Ueda M (2019) Early diagnosis of ATTR amyloidosis through targeted follow-up of identified carriers of TTR gene mutations. Amyloid 26(1):3\u20139. https:\/\/doi.org\/10.1080\/13506129.2018.1556156","journal-title":"Amyloid"},{"issue":"Suppl 1","key":"7793_CR14","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3109\/13506129.2012.685665","volume":"19","author":"D Adams","year":"2012","unstructured":"Adams D, Lozeron P, Th\u00e9audin M, Mincheva Z, Cauquil C, Adam C, Signate A, Vial C, Maisonobe T, Delmont E, Franques J (2012) Regional difference and similarity of familial amyloidosis with polyneuropathy in France. Amyloid 19(Suppl 1):61\u201364. https:\/\/doi.org\/10.3109\/13506129.2012.685665","journal-title":"Amyloid"},{"issue":"5","key":"7793_CR15","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1136\/jnnp-2016-315262","volume":"88","author":"A Cortese","year":"2017","unstructured":"Cortese A, Vegezzi E, Lozza A, Alfonsi E, Montini A, Moglia A, Merlini G, Obici L (2017) Diagnostic challenges in hereditary transthyretin amyloidosis with polyneuropathy: avoiding misdiagnosis of a treatable hereditary neuropathy. J Neurol Neurosurg Psychiatry 88(5):457\u2013458. https:\/\/doi.org\/10.1136\/jnnp-2016-315262","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"7793_CR16","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1002\/ana.24519","volume":"78","author":"LL Mariani","year":"2015","unstructured":"Mariani LL, Lozeron P, Th\u00e9audin M, Mincheva Z, Signate A, Ducot B, Algalarrondo V, Denier C, Adam C, Nicolas G, Samuel D (2015) Genotype-phenotype correlation and course of transthyretin familial amyloid polyneuropathies in France. Ann Neurol 78(6):901\u2013916. https:\/\/doi.org\/10.1002\/ana.24519","journal-title":"Ann Neurol"},{"issue":"Suppl 1","key":"7793_CR17","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1097\/WCO.0000000000000289","volume":"29","author":"D Adams","year":"2016","unstructured":"Adams D, Suhr OB, Hund E, Obici L, Tournev I, Campistol JM, Slama MS, Hazenberg BP, Coelho T (2016) First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy. Curr Opin Neurol 29(Suppl 1):S14-26. https:\/\/doi.org\/10.1097\/WCO.0000000000000289","journal-title":"Curr Opin Neurol"},{"issue":"3","key":"7793_CR18","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1080\/13506120802193720","volume":"15","author":"U Hellman","year":"2008","unstructured":"Hellman U, Alarcon F, Lundgren HE, Suhr OB, Bona\u00efti-Pelli\u00e9 C, Plant\u00e9-Bordeneuve V (2008) Heterogeneity of penetrance in familial amyloid polyneuropathy, ATTR Val30Met, in the Swedish population. Amyloid 15(3):181\u2013186. https:\/\/doi.org\/10.1080\/13506120802193720","journal-title":"Amyloid"},{"issue":"11","key":"7793_CR19","doi-asserted-by":"publisher","first-page":"e120","DOI":"10.1136\/jmg.40.11.e120","volume":"40","author":"V Plant\u00e9-Bordeneuve","year":"2003","unstructured":"Plant\u00e9-Bordeneuve V, Carayol J, Ferreira A, Adams D, Clerget-Darpoux F, Misrahi M, Said G, Bonaiti-Pellie C (2003) Genetic study of transthyretin amyloid neuropathies: carrier risks among French and Portuguese families. J Med Genet 40(11):e120. https:\/\/doi.org\/10.1136\/jmg.40.11.e120","journal-title":"J Med Genet"},{"issue":"4","key":"7793_CR20","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1136\/jmg.31.4.293","volume":"31","author":"T Coelho","year":"1994","unstructured":"Coelho T, Sousa A, Louren\u00e7o E, Ramalheira J (1994) A study of 159 Portuguese patients with familial amyloidotic polyneuropathy (FAP) whose parents were both unaffected. J Med Genet 31(4):293\u2013299. https:\/\/doi.org\/10.1136\/jmg.31.4.293","journal-title":"J Med Genet"},{"issue":"7","key":"7793_CR21","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1212\/01.wnl.0000267338.45673.f4","volume":"69","author":"V Plant\u00e9-Bordeneuve","year":"2007","unstructured":"Plant\u00e9-Bordeneuve V, Ferreira A, Lalu T, Zaros C, Lacroix C, Adams D, Said G (2007) Diagnostic pitfalls in sporadic transthyretin familial amyloid polyneuropathy (TTR-FAP). Neurology 69(7):693\u2013698. https:\/\/doi.org\/10.1212\/01.wnl.0000267338.45673.f4","journal-title":"Neurology"},{"issue":"2","key":"7793_CR22","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1002\/path.2411","volume":"216","author":"E Ihse","year":"2008","unstructured":"Ihse E, Ybo A, Suhr OB, Lindqvist P, Backman C, Westermark P (2008) Amyloid fibril composition is related to the phenotype of hereditary transthyretin V30M amyloidosis. J Pathol 216(2):253\u2013261. https:\/\/doi.org\/10.1002\/path.2411","journal-title":"J Pathol"},{"issue":"1","key":"7793_CR23","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1212\/01.wnl.0000132966.36437.12","volume":"63","author":"H Koike","year":"2004","unstructured":"Koike H, Misu K, Sugiura M, Iijima M, Mori K, Yamamoto M, Hattori N, Mukai E, Ando Y, Ikeda S, Sobue G (2004) Pathology of early- vs late-onset TTR Met30 familial amyloid polyneuropathy. Neurology 63(1):129\u2013138. https:\/\/doi.org\/10.1212\/01.wnl.0000132966.36437.12","journal-title":"Neurology"},{"issue":"10","key":"7793_CR24","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1002\/lt.21817","volume":"15","author":"S Okamoto","year":"2009","unstructured":"Okamoto S, Wixner J, Obayashi K, Ando Y, Ericzon BG, Friman S, Uchino M, Suhr OB (2009) Liver transplantation for familial amyloidotic polyneuropathy: impact on Swedish patients\u2019 survival. Liver Transpl 15(10):1229\u20131235. https:\/\/doi.org\/10.1002\/lt.21817","journal-title":"Liver Transpl"},{"issue":"5","key":"7793_CR25","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1097\/WCO.0b013e328357bdf6","volume":"25","author":"D Adams","year":"2012","unstructured":"Adams D, Lozeron P, Lacroix C (2012) Amyloid neuropathies. Curr Opin Neurol 25(5):564\u2013572. https:\/\/doi.org\/10.1097\/WCO.0b013e328357bdf6","journal-title":"Curr Opin Neurol"},{"issue":"9","key":"7793_CR26","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1136\/jnnp-2014-308724","volume":"86","author":"Y Sekijima","year":"2015","unstructured":"Sekijima Y (2015) Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments. J Neurol Neurosurg Psychiatry 86(9):1036\u20131043. https:\/\/doi.org\/10.1136\/jnnp-2014-308724","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"7793_CR27","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/1750-1172-8-31","volume":"8","author":"Y Ando","year":"2013","unstructured":"Ando Y, Coelho T, Berk JL, Cruz MW, Ericzon BG, Ikeda SI, Lewis WD, Obici L, Plant\u00e9-Bordeneuve V, Rapezzi C, Said G (2013) Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis 8:31. https:\/\/doi.org\/10.1186\/1750-1172-8-31","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"7793_CR28","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1136\/jnnp-2021-327909","volume":"93","author":"A Carroll","year":"2022","unstructured":"Carroll A, Dyck PJ, de Carvalho M, Kennerson M, Reilly MM, Kiernan MC, Vucic S (2022) Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis. J Neurol Neurosurg Psychiatry 93(6):668\u201378. https:\/\/doi.org\/10.1136\/jnnp-2021-327909","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"7793_CR29","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/jns.12153","volume":"21","author":"I Concei\u00e7\u00e3o","year":"2016","unstructured":"Concei\u00e7\u00e3o I, Gonz\u00e1lez-Duarte A, Obici L, Schmidt HH, Simoneau D, Ong ML, Amass L (2016) \u201cRed-flag\u201d symptom clusters in transthyretin familial amyloid polyneuropathy. J Peripher Nerv Syst 21(1):5\u20139. https:\/\/doi.org\/10.1111\/jns.12153","journal-title":"J Peripher Nerv Syst"},{"issue":"Suppl 1","key":"7793_CR30","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s10286-019-00627-7","volume":"29","author":"I Bentellis","year":"2019","unstructured":"Bentellis I, Amarenco G, Gam\u00e9 X, Jericevic D, El-Akri M, Voiry C, Freton L, Hascoet J, Alimi Q, Kerdraon J, Brucker BM (2019) Diagnosis and treatment of urinary and sexual dysfunction in hereditary TTR amyloidosis. Clin Auton Res 29(Suppl 1):65\u201374. https:\/\/doi.org\/10.1007\/s10286-019-00627-7","journal-title":"Clin Auton Res"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-024-07793-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-024-07793-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-024-07793-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T09:15:46Z","timestamp":1737969346000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-024-07793-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,10]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["7793"],"URL":"https:\/\/doi.org\/10.1007\/s10072-024-07793-1","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,10]]},"assertion":[{"value":"15 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics committee of the CENTRO ACAD\u00c9MICO DE LISBOA\u2014(Ref 1117\/13). All participants signed an informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"We confirm that we have read the Journal\u2019s position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Publication"}},{"value":"The authors have no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"None of the authors has any conflict of interest to disclose.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}